

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims.

1. (Previously Presented) An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) a polynucleotide fragment of SEQ ID NO:1, 3, or 5, or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No: 97128;
 - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2, 4, or 6, or the cDNA sequence included in ATCC Deposit No: 97128;
 - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2, 4, or 6 or the cDNA sequence included in ATCC Deposit No: 97128;
 - (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2, 4, or 6, or the cDNA sequence included in ATCC Deposit No: 97128;
 - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:2, 4, or 6, or the cDNA sequence included in ATCC Deposit No: 97128 having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:1, 3, or 5;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:1, 3, or 5;
 - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:2, 4, or 6;
 - (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2-10. (Canceled).

11. (Previously Presented) An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) a polypeptide fragment of SEQ ID NO: 2, 4, or 6 or the encoded sequence included in ATCC Deposit No: 97128;
 - (b) a polypeptide fragment of SEQ ID NO: 2, 4, or 6, or the encoded sequence included in ATCC Deposit No: 97128 having biological activity;
 - (c) a polypeptide domain of SEQ ID NO: 2, 4, or 6 or the encoded sequence included in ATCC Deposit No: 97128;
 - (d) a polypeptide epitope of SEQ ID NO: 2, 4, or 6 or the encoded sequence included in ATCC Deposit No: 97128;
 - (e) a mature form of a secreted protein;
 - (f) a full length secreted protein;
 - (g) a variant of SEQ ID NO: 2, 4, or 6;
 - (h) an allelic variant of SEQ ID NO: 2, 4, or 6; or
 - (i) a species homologue of the SEQ ID NO: 2, 4, or 6.
12. (Canceled).
13. (Previously Presented) An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. (Canceled).
15. (Currently Amended) A method of making an isolated polypeptide comprising:
- (a) culturing a recombinant host cell ~~of claim 14~~ that expresses the isolated polypeptide of claim 11 under conditions such that said polypeptide is expressed; and
 - (b) recovering said polypeptide.
16. (Canceled).
17. (Previously Presented) A method for preventing, treating, or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.

18. (Previously Presented) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising:
 - (a) determining the presence or absence of a mutation in the polynucleotide of claim 1;
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
19. (Previously Presented) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising:
 - (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample;
 - (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
20. (Previously Presented) A method for identifying binding partner to the polypeptide of claim 11 comprising:
 - (a) contacting the polypeptide of claim 11 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.
21. (Canceled).
22. (Previously Presented) A method of identifying an activity in a biological assay, wherein the method comprises:
 - (a) expressing SEQ ID NO:1, 3, or 5 in a cell;
 - (b) isolating the supernatant;
 - (c) detecting an activity in a biological assay; and
 - (d) identifying the protein in the supernatant having the activity.
23. (Previously Presented) The product produced by the method of claim 22.

24. (Previously Presented) A method for preventing, treating, or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.
25. (Canceled).
26. (New) An isolated protein comprising amino acid residues 2 to 425 of SEQ ID NO:2.
27. (New) The isolated protein of claim 26 which comprises amino acid residues 1 to 425 of SEQ ID NO:2.
28. (New) The isolated protein of claim 26, which further comprises a heterologous polypeptide sequence.
29. (New) A composition comprising the isolated protein of claim 26 and a carrier.
30. (New) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 26 by a cell; and
 - (b) recovering said protein.
31. (New) The isolated protein of claim 26 wherein said isolated protein is glycosylated.
32. (New) An isolated protein comprising the amino acid sequence of the complete polypeptide encoded by the Human Neuropeptide Receptor cDNA contained in ATCC Deposit No. 97128, excepting the N-terminal methionine.
33. (New) The isolated protein of claim 32 which comprises the amino acid sequence of the complete polypeptide encoded by the Human Neuropeptide Receptor cDNA contained in ATCC Deposit No. 97128.

34. (New) The isolated protein of claim 32, which further comprises a heterologous polypeptide sequence.
35. (New) A composition comprising the isolated protein of claim 32 and a carrier.
36. (New) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 32 by a cell; and
 - (b) recovering said protein.
37. (New) The isolated protein of claim 32 wherein said isolated protein is glycosylated.
38. (New) An isolated protein comprising a polypeptide which is at least 95% identical to amino acid residues 1 to 425 of SEQ ID NO:2.
39. (New) The isolated protein of claim 38, which further comprises a heterologous polypeptide sequence.
40. (New) A composition comprising the isolated protein of claim 38 and a carrier..
41. (New) An isolated protein produced by the method comprising:
- (a) expressing the protein of claim 38 by a cell; and,
 - (b) recovering said protein.
42. (New) The isolated protein of claim 38 wherein said isolated protein is glycosylated.
43. (New) An isolated protein comprising a polypeptide which is at least 95% identical to the complete polypeptide encoded by the Human Neuropeptide Receptor cDNA contained in ATCC Deposit No. 97128
44. (New) The isolated protein of claim 43, which further comprises a heterologous polypeptide sequence.

45. (New) A composition comprising the isolated protein of claim 43 and a carrier.

46. (New) An isolated protein produced by the method comprising:

- (a) expressing the protein of claim 43 by a cell; and
- (b) recovering said protein.

47. (New) The isolated protein of claim 43 wherein said isolated protein is glycosylated.